Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cinclus Pharma Holding AB ( (SE:CINPHA) ) has issued an announcement.
Cinclus Pharma Holding AB’s Nomination Committee has proposed co-founder Kjell Andersson as a new Board member, succeeding Peter Unge, who will transition to the Scientific Advisory Board. This change comes as the company reaches a pivotal milestone with the initiation of its first Phase III study, highlighting the strategic continuity and expertise Kjell brings to the Board, which is crucial for the company’s ongoing development and industry positioning.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and disorders of the upper gastrointestinal tract. Their leading drug candidate, linaprazan glurate, is designed to treat gastroesophageal reflux disease (GERD) more effectively than current treatments. The company is advancing its first Phase III study, targeting a significant market need in the US and EU.
Average Trading Volume: 61,184
Technical Sentiment Signal: Hold
Current Market Cap: SEK813.5M
For a thorough assessment of CINPHA stock, go to TipRanks’ Stock Analysis page.